Who Owns GoodRx Company?

GoodRx Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns GoodRx today?

GoodRx’s ownership shifted from founders to a broad public base after its September 2020 IPO, with founders and employees retaining meaningful stakes while large institutions and mutual funds now hold sizable positions.

As of 2024–2025 GoodRx reports roughly $740–$760 million in annual revenue; major shareholders include mutual funds, ETFs, and insiders, while the company still operates its prescription savings marketplace and telehealth services — see GoodRx Porter's Five Forces Analysis.

Founders and Early Ownership of the company began with Trevor Bezdek (technology and product), Douglas Hirsch (consumer internet and operations) and Scott Marlette (engineering) forming the business in 2011; the trio held majority founder equity at inception with a seed-stage cap table and an option pool for early hires.

Founding Team Roles

Trevor Bezdek led product and technology, Douglas Hirsch managed consumer and operations, and Scott Marlette led engineering during early years.

Initial Equity Concentration

Founders controlled a majority of equity at formation; exact percentages were not publicly disclosed but matched typical seed-stage concentration.

Seed Capital Sources

Early capital came from angel and seed investors within Los Angeles and Silicon Valley networks supporting initial product-market fit and growth.

Vesting & Options

Founders entered standard four-year vesting with one-year cliffs and created an employee option pool to attract senior engineering and commercial talent.

Capital Efficiency

Pre-IPO growth relied on comparatively modest external capital and emphasis on profitability and unit economics versus high-burn peers.

Founders' Liquidity

Founder liquidity mainly occurred around the IPO and later secondary windows rather than early-stage recapitalizations or forced sales.

The founding team's shared consumer-first, data-driven vision supported a stable early control structure with no public record of founder disputes; governance and dilution evolved through later financing and the IPO process.

Key Early Ownership Facts

Founders maintained concentrated control early, structured standard vesting, and prioritized sustainable unit economics leading into public markets.

• Founders: Trevor Bezdek, Douglas Hirsch, Scott Marlette
• Formation: 2011, majority founder equity at inception
• Early funding: angels and seed investors from LA and Silicon Valley
• Liquidity: primary founder exits aligned with IPO and secondary windows

For more on corporate culture and leadership principles see Mission, Vision & Core Values of GoodRx

GoodRx SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events shaping who owns GoodRx include its 2020 NASDAQ IPO, progressive public float expansion 2021–2023 with rising passive index ownership, and 2023–2025 concentration of institutional stakes that reduced insiders' percentage while founders remained material holders.

As of 2024–2025 SEC filings and proxy disclosures show founders Douglas Hirsch and Trevor Bezdek remain significant individual shareholders and executive directors, Scott Marlette holds a smaller residual stake, and combined founder ownership diluted from double digits at IPO to mid‑high single digits individually with aggregate ownership in the low‑mid teens.

Major shareholders and shifts

Institutional concentration and equity compensation changed GoodRx ownership structure, increasing passive funds' voting weight and directing strategic priorities toward stable revenue streams.

• Founders: Douglas Hirsch and Trevor Bezdek — continued meaningful stakes; aggregate founders ~low‑mid teens percent (proxy ranges)
• Largest institutions: Vanguard and BlackRock — often >15–20% combined alongside State Street and major index ETFs
• Employees/directors: material holdings via RSUs/options under ongoing equity programs
• Voting & governance: passive funds' rise increased scrutiny on cash flow predictability, PBM compliance, and diversification into provider/pharmaceutical solutions

For ownership filings, 13F reports and annual proxy statements are primary sources; for market context and competitor positioning see Competitors Landscape of GoodRx.

GoodRx PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of 2024–2025 the GoodRx board includes co‑founders Douglas Hirsch and Trevor Bezdek plus independent directors with healthcare, payer, technology and consumer expertise; the chair and committee leads are independent to align with post‑IPO governance norms.

GoodRx uses a one‑share‑one‑vote structure with Class A common shares; there was no enduring supervoting/dual‑class design at IPO, so founders influence governance as directors/operators rather than via outsized voting rights. Shareholder debates in 2023–2025 focused on compensation alignment, data usage and partner concentration risk, with Say‑on‑Pay votes and director re‑elections reflecting mainstream advisory input (ISS/Glass Lewis).

Board and Voting Power — Key Points

Voting power at GoodRx is dispersed; founders are influential but not controlling through special votes. Institutional investors steer policy via proxies and engagement rather than board seats.

• Board composition includes co‑founders and independent chair/committee leads
• Capital structure: one‑share‑one‑vote (Class A common shares)
• Major institutional shareholders (Vanguard, BlackRock, State Street) influence governance via proxy voting
• No major proxy contests reported in 2023–2025; governance focus on pay, data, partner risk

For ownership history and timeline including IPO details and founder stakes see Brief History of GoodRx.

GoodRx Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Ownership of GoodRx has trended toward greater passive institutional exposure and diluted founder stakes since the IPO, with recent years showing portfolio rotations, modest employee equity refreshes, and insider secondary sales that preserved public independence.

Industry context: institutional ownership in U.S. mid-cap healthtech is elevated, founder stakes typically decline post-IPO, and activists target profitability and partner concentration; analysts expect GoodRx to remain public and independent with management emphasizing organic growth, partnerships, and disciplined tuck-ins.

Passive ownership rise

Index inclusion kept GoodRx in ETFs, lifting passive holdings and smoothing liquidity despite active rotation after 2022 disruption.

Employee ownership changes

Equity compensation and refresh grants modestly increased employee stakes, aligning incentives while diluting legacy holders within authorized limits.

Capital allocation priorities

Cash prioritized for product investment and selective M&A in provider and pharma solutions rather than a broad buyback program.

Future ownership drivers

ETF/index flows, performance vs guidance, and potential strategic investors from pharmacy, PBM, or pharma ecosystems will likely dictate future shifts in who owns GoodRx; see additional context in Growth Strategy of GoodRx.

GoodRx Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔